QbD elements not implemented during global harmonization – CAPA for guideline non-compliance


Published on 02/02/2026

Implementing Quality by Design (QbD) Elements for Global Harmonization Compliance

The pharmaceutical landscape has undergone a significant transformation with the evolution of Global Harmonization, aiming to elevate quality standards. However, not all organizations adequately implement Quality by Design (QbD) principles during this transition. Non-compliance with these principles can shake the foundation of Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) requirements, resulting in regulatory scrutiny and potential penalties from authorities such as FDA, EMA, and MHRA. This article provides a comprehensive playbook for addressing QbD elements not implemented during the global harmonization process.

For deeper guidance and related home-care methods, check this ICH Guidelines & Global Frameworks.

Following this playbook, professionals in Manufacturing, Quality Control (QC), Quality Assurance (QA), Engineering, and Regulatory Affairs (RA) will be equipped to recognize symptoms of non-compliance, uncover root causes, and establish robust corrective action and preventive action (CAPA) plans. The goal is to foster compliance that meets both regulatory expectations and

organizational standards.

Symptoms/Signals on the Floor or in the Lab

Identifying symptoms of non-compliance with QbD elements is the first step towards rectification. Here are some common signals:

  • Inconsistent Product Quality: Variations in batch-release testing results may indicate improper implementation of QbD principles.
  • Frequent Deviations: A spike in deviations reported in batch records can signal a lack of adherence to prescribed QbD processes.
  • Insufficient Risk Assessments: Inconsistencies in the documentation of risk assessments may highlight that essential QbD principles were overlooked.
  • Redundant Testing: Excessive or unnecessary testing could suggest that quality systems are not robustly integrated with QbD methodologies.
  • Unclear Specifications: Vague or poorly defined critical quality attributes (CQAs) might indicate that QbD approaches were not adequately applied.

Likely Causes

The causes of QbD elements not being implemented could be categorized into several groups:

Pharma Tip:  Lifecycle approach missing during global harmonization – alignment with ICH expectations
Category Likely Causes
Materials Lack of material characterization, inadequate supplier qualifications.
Method Unvalidated analytical methods, poor method transfer procedures.
Machine Equipment not suitable for product requirements, outdated technology.
Man Poorly trained personnel, lack of understanding of QbD principles.
Measurement Inaccurate measurement systems, poorly defined measurement criteria.
Environment Inadequate control of environmental conditions impacting product quality.

Immediate Containment Actions (first 60 minutes)

Taking swift action is essential for mitigating risks associated with non-compliance. Here’s a structured approach for immediate containment:

  1. Notify Key Stakeholders: Inform QA, production supervisors, and department heads about the observed symptoms.
  2. Stop Production: Halt manufacturing processes that are suspected of non-compliance until an initial assessment is conducted.
  3. Isolate Affected Product: Segregate all affected batches from compliant products to prevent cross-contamination.
  4. Conduct a Preliminary Investigation: Gather initial information regarding the symptoms, including batch records, test results, and operational logs.
  5. Document Actions: Record all actions and observations for subsequent investigation and regulatory review.

Investigation Workflow

Conducting a thorough investigation is crucial to identify the underlying issues that led to the non-implementation of QbD principles. Follow this investigation workflow:

  1. Collect Relevant Data: Gather data from manufacturing records, QC tests, personnel training logs, and any other relevant documents.
  2. Interview Personnel: Engage with employees involved in the affected processes to understand their observations and actions taken.
  3. Analyze Data: Review collected data to find patterns or anomalies that point to root causes. Look for correlations between symptoms and possible causal factors.
  4. Identify Gaps: Pay close attention to missed QbD principles, such as insufficient risk assessments or unclear specifications.
  5. Document Findings: Record findings clearly, including data trends and employee feedback for future reference.

Root Cause Tools (5-Why, Fishbone, Fault Tree) and When to Use Which

Effective root cause analysis requires the application of suitable tools. Below is an overview of three widely used methods:

  • 5-Why Analysis: Utilize this method for straightforward issues where asking “why” can lead directly to the root cause. Best used for single issue investigations.
  • Fishbone Diagram: Use this tool when multiple causes may be contributing to the problem. It helps categorize potential causes into areas like man, method, machine, etc., allowing a more comprehensive view.
  • Fault Tree Analysis: Ideal for complex failures involving multiple systems. This tool provides a top-down approach, allowing detailed analysis of system failures and the relationships between different components.
Pharma Tip:  Guideline version conflicts during inspection – alignment with ICH expectations

CAPA Strategy (Correction, Corrective Action, Preventive Action)

The CAPA process is pivotal for addressing non-compliance. Here’s how to approach it:

  1. Correction: Take immediate actions to rectify the symptoms observed. For example, adjust the processes to meet established specifications.
  2. Corrective Action: Implement actions designed to prevent recurrence. This could include remedial training for personnel or revising standard operating procedures (SOPs) to integrate QbD principles.
  3. Preventive Action: Focus on long-term solutions such as regular QbD audits, risk assessments, or updates to the quality management system to ensure compliance remains robust.

Control Strategy & Monitoring (SPC/Trending, Sampling, Alarms, Verification)

To ensure ongoing compliance, a robust control strategy is necessary. The following elements should be integrated into the quality processes:

Related Reads

  • Statistical Process Control (SPC): Employ SPC techniques to monitor processes proactively. This allows for early intervention if trends indicate potential non-compliance.
  • Sampling Plans: Create risk-based sampling plans that take QbD principles into account, ensuring the critical quality attributes of products are consistently checked.
  • Alarms and Alerts: Utilize automated systems to set alarms when critical parameters deviate from established ranges, enabling swift corrective actions.
  • Verification: Conduct periodic assessments to verify that implemented controls effectively prevent issues related to non-compliance with QbD principles.

Validation / Re-qualification / Change Control Impact (When Needed)

Changes made to rectify non-compliance should trigger a review of validation and change control processes. Consider the following:

  1. Validation Updates: If a change impacts the product or process, ensure validation protocols are updated accordingly, including re-qualification of equipment and methods.
  2. Re-Qualification: Evaluate whether existing qualifications remain applicable with changes made. New data must be generated to support claims of continued compliance.
  3. Change Control Processes: Document all changes thoroughly and ensure that stakeholder reviews occur to align on QbD principles moving forward.
Pharma Tip:  QbD elements not implemented during development – inspection questioning scenarios

Inspection Readiness: What Evidence to Show

Regulatory bodies will expect substantial evidence of compliance during inspections. Maintain the following documentation:

  • Records: Keep comprehensive records of all quality testing, investigations, and closure activities.
  • Logs: Secure logs of operational metrics, including any deviations, immediate actions taken, and effectiveness checks.
  • Batch Documentation: Ensure batch production records detail compliance with QbD principles.
  • Deviation Reports: Document deviations, investigations into root causes, and resultant CAPA activities thoroughly.

FAQs

What are QbD elements?

QbD elements include understanding product performance, identifying and controlling variables that affect product quality, and creating a consistent manufacturing process.

How can I improve compliance with QbD principles in my organization?

Implement training programs, update SOPs, enhance cross-department collaboration, and utilize risk assessments effectively.

What are the consequences of not implementing QbD?

Consequences include regulatory penalties, product recalls, and adverse impacts on quality and safety, leading to loss of market trust.

How often should QbD elements be reviewed and updated?

QbD elements should be reviewed regularly, especially whenever critical changes are made to processes, products, or regulations.

Can CAPA address both corrective and preventive actions simultaneously?

Yes, a well-structured CAPA system targets both immediate corrections and long-term preventive measures to prevent recurrence.

Is training necessary for all personnel in QbD compliance?

Yes, all personnel involved in any part of the relevant processes should be trained in QbD principles to ensure comprehensive understanding and adherence.

What is a critical quality attribute (CQA)?

A CQA is a physical, chemical, or microbiological property or characteristic that needs to be controlled to ensure that the product meets its intended safety and efficacy.

How do I conduct effective risk assessments related to QbD?

Use a structured approach to identify potential risks, determine their impact, and establish control mechanisms to mitigate those risks comprehensively.